Investigating the role of epigenetics in chronic myeloid leukemia resistance to treatment
Collection of Biological Resources During Medical Care of Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase for an Epigenetic Study of Leukemic Stem Cells
This study is trying to find out why some leukemia stem cells survive treatment in newly diagnosed patients with chronic myeloid leukemia, to help develop better therapies.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 160 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Clermont-Ferrand Academic / other |
| Locations | 16 sites (Annecy and 15 other locations) |
| Trial ID | NCT03481868 on ClinicalTrials.gov |
What this trial studies
This study aims to identify the epigenetic dysregulations that contribute to the survival of chronic myeloid leukemia (CML) stem cells despite treatment with tyrosine kinase inhibitors (TKIs). It focuses on patients newly diagnosed with CML in the chronic phase who have not yet received treatment. By collecting blood and bone marrow samples, researchers will explore the mechanisms behind the persistence of leukemic stem cells and their resistance to TKIs. The findings could provide insights into the biological status of these cells and potential new therapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been newly diagnosed with chronic myeloid leukemia in the chronic phase and have not yet received any treatment.
Not a fit: Patients who have already been treated for chronic myeloid leukemia or have contraindications to the use of TKIs may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with chronic myeloid leukemia by addressing the mechanisms of resistance.
How similar studies have performed: Other studies have indicated the importance of epigenetic factors in cancer treatment resistance, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient newly diagnosed for Chronic Myeloid Leukemia in chronic phase * Patient older than 18 years old * Patient who received no treatment for CML at the time of sampling on D0 * Intention of prescription with first-line treatment with TKI only * Choice of first-line CML treatment by TKI only * Patient having signed an informed consent * Patient with a social security system Exclusion Criteria: * Contra-indication to the use of TKI * Probability of poor compliance during treatment * Patients already treated for CML
Where this trial is running
Annecy and 15 other locations
- CHU Annecy-Genevois — Annecy, France (Recruiting)
- Institut Bergonié — Bordeaux, France (Recruiting)
- CHU Caen — Caen, France (Recruiting)
- CHU Clermont-Ferrand — Clermont-Ferrand, France (Recruiting)
- CHU Grenoble Alpes — Grenoble, France (Recruiting)
- CHU Lille — Lille, France (Recruiting)
- Centre Léon Bérard — Lyon, France (Recruiting)
- Hospices Civils de Lyon — Lyon, France (Recruiting)
- CHU Nancy — Nancy, France (Recruiting)
- CHU Nice — Nice, France (Recruiting)
- Hôpital Bicêtre — Paris, France (Recruiting)
- Hôpital Henri Mondor — Paris, France (Recruiting)
- Hôpital Paul Brousse — Paris, France (Recruiting)
- Hôpital Saint Louis — Paris, France (Recruiting)
- CHU Saint-Etienne — Saint-Étienne, France (Recruiting)
- CHU Versailles — Versailles, France (Recruiting)
Study contacts
- Principal investigator: Marc BERGER — University Hospital, Clermont-Ferrand
- Study coordinator: Patrick LACARIN
- Email: placarin@chu-clermontferrand.fr
- Phone: 04 73 75 11 95
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.